Corcept Therapeutics Incorporated (CORT) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
117.47
↑+195% vs avg
5yr avg: 39.76
30Y Low12.8·High87.0
P/FCF
↑
39.49
↑+62% vs avg
5yr avg: 24.36
30Y Low11.0·High171.0
P/B Ratio
↓
9.66
↑+45% vs avg
5yr avg: 6.67
30Y Low2.2·High28.8
ROE
↓
15.0%
↑-30% vs avg
5yr avg: 21.6%
30Y Low-356%·High111%
Debt/EBITDA
↑
0.13
↑+233% vs avg
5yr avg: 0.04
30Y Low0.0·High1.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CORT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Corcept Therapeutics Incorporated trades at 63.6x earnings, 94% above its 5-year average of 32.7x, sitting at the 90th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 187%. On a free-cash-flow basis, the stock trades at 39.5x P/FCF, 62% above the 5-year average of 24.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.6B | $4.2B | $5.7B | $3.6B | $2.4B | $2.5B | $3.2B | $1.5B | $1.7B | $2.2B | $843M |
| Enterprise Value | $5.5B | $4.1B | $5.6B | $3.5B | $2.3B | $2.4B | $3.2B | $1.5B | $1.5B | $2.1B | $806M |
| P/E Ratio → | 63.60 | 42.44 | 40.97 | 34.55 | 23.34 | 22.25 | 30.78 | 15.71 | 22.27 | 17.37 | 103.71 |
| P/S Ratio | 7.35 | 5.48 | 8.47 | 7.52 | 5.86 | 6.81 | 9.18 | 4.84 | 6.74 | 14.13 | 10.37 |
| P/B Ratio | 9.66 | 6.45 | 8.41 | 7.16 | 4.69 | 6.64 | 6.21 | 4.00 | 6.14 | 11.78 | 20.38 |
| P/FCF | 39.49 | 29.45 | 29.19 | 28.60 | 19.64 | 14.90 | 21.55 | 10.98 | 14.67 | 37.16 | 46.34 |
| P/OCF | 39.43 | 29.41 | 28.87 | 28.57 | 19.57 | 14.86 | 21.38 | 10.90 | 14.63 | 36.90 | 45.85 |
P/E links to full P/E history page with 30-year chart
CORT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Corcept Therapeutics Incorporated's enterprise value stands at 117.5x EBITDA, 195% above its 5-year average of 39.8x. The Healthcare sector median is 14.1x, placing the stock at a 731% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.33 | 8.29 | 7.24 | 5.70 | 6.60 | 8.97 | 4.75 | 5.91 | 13.47 | 9.91 |
| EV / EBITDA | 117.47 | 86.99 | 40.48 | 32.25 | 20.11 | 18.95 | 24.34 | 12.79 | 16.56 | 40.50 | 78.54 |
| EV / EBIT | 122.42 | 90.66 | 40.87 | 32.57 | 20.33 | 19.33 | 24.77 | 13.04 | 16.60 | 40.58 | 80.08 |
| EV / FCF | — | 28.64 | 28.57 | 27.53 | 19.10 | 14.44 | 21.07 | 10.78 | 12.88 | 35.44 | 44.31 |
CORT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Corcept Therapeutics Incorporated earns an operating margin of 5.9%. Operating margins have compressed from 22.2% to 5.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 15.0% indicates solid capital efficiency. ROIC of 6.2% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating Margin | 5.9% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% |
| Net Profit Margin | 13.1% | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | 15.0% | 23.6% | 21.0% | 23.1% | 25.0% | 23.7% | 29.1% | 32.3% | 111.1% | 27.2% |
| ROA | 11.9% | 11.9% | 19.1% | 17.6% | 20.1% | 22.6% | 21.5% | 26.0% | 28.3% | 89.3% | 13.5% |
| ROIC | 6.2% | 6.2% | 22.1% | 19.9% | 23.0% | 24.9% | 24.2% | 40.6% | 86.0% | 86.7% | — |
| ROCE | 6.5% | 6.5% | 22.5% | 20.9% | 25.4% | 27.6% | 28.6% | 34.4% | 38.3% | 45.5% | 28.1% |
CORT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Corcept Therapeutics Incorporated carries a Debt/EBITDA ratio of 0.1x, which is very conservative (96% below the sector average of 3.3x). The company holds a net cash position — cash of $120M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | 0.35 |
| Debt / EBITDA | 0.13 | 0.13 | 0.05 | 0.00 | 0.01 | 0.00 | 0.02 | 0.03 | — | — | 1.43 |
| Net Debt / Equity | — | -0.18 | -0.18 | -0.27 | -0.13 | -0.21 | -0.14 | -0.07 | -0.75 | -0.54 | -0.89 |
| Net Debt / EBITDA | -2.45 | -2.45 | -0.87 | -1.25 | -0.57 | -0.60 | -0.56 | -0.24 | -2.30 | -1.96 | -3.59 |
| Debt / FCF | — | -0.81 | -0.62 | -1.07 | -0.54 | -0.46 | -0.49 | -0.21 | -1.79 | -1.72 | -2.03 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | 1078.67 | 4.94 |
Net cash position: cash ($120M) exceeds total debt ($6M)
CORT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Corcept Therapeutics Incorporated's current ratio of 2.92x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.39x to 2.92x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.92 | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 10.07 | 7.91 | 6.72 | 4.75 | 2.40 |
| Quick Ratio | 2.85 | 2.85 | 3.26 | 4.31 | 6.80 | 5.50 | 9.97 | 7.77 | 6.26 | 4.47 | 2.31 |
| Cash Ratio | 2.24 | 2.24 | 2.72 | 3.52 | 5.95 | 4.70 | 9.28 | 7.10 | 5.77 | 3.52 | 1.88 |
| Asset Turnover | — | 0.91 | 0.80 | 0.78 | 0.69 | 0.86 | 0.62 | 0.74 | 0.81 | 0.72 | 1.18 |
| Inventory Turnover | 1.01 | 1.01 | 0.88 | 0.84 | 0.88 | 1.06 | 1.14 | 1.01 | 0.32 | 0.42 | 0.88 |
| Days Sales Outstanding | — | 28.66 | 31.40 | 43.00 | 42.56 | 28.95 | 27.02 | 23.73 | 25.55 | 64.64 | 44.26 |
CORT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Corcept Therapeutics Incorporated returns 4.4% to shareholders annually primarily through share buybacks. The earnings yield of 1.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.6% | 2.4% | 2.4% | 2.9% | 4.3% | 4.5% | 3.2% | 6.4% | 4.5% | 5.8% | 1.0% |
| FCF Yield | 2.5% | 3.4% | 3.4% | 3.5% | 5.1% | 6.7% | 4.6% | 9.1% | 6.8% | 2.7% | 2.2% |
| Buyback Yield | 4.4% | 5.9% | 0.3% | 4.0% | 0.0% | 11.9% | 0.3% | 2.1% | 1.4% | 0.0% | 0.0% |
| Total Shareholder Yield | 4.4% | 5.9% | 0.3% | 4.0% | 0.0% | 11.9% | 0.3% | 2.1% | 1.4% | 0.0% | 0.0% |
| Shares Outstanding | — | $120M | $113M | $112M | $116M | $126M | $124M | $123M | $127M | $125M | $116M |
Peer Comparison
Compare CORT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CORTYou | $6B | 63.6 | 117.5 | 39.5 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 HRMY | $2B | 12.1 | 5.0 | 5.4 | 77.2% | 24.0% | 20.8% | 59.5% | 0.1 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 49.3 | 19.7 | 56.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 VNDA | $440M | -2.0 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 OSUR | $216M | -3.2 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 AXSM | $11B | -60.5 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
See CORT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CORT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CORT vs INVA
Side-by-side business, growth, and profitability comparison vs Innoviva, Inc..
Start ComparisonCORT — Frequently Asked Questions
Quick answers to the most common questions about buying CORT stock.
What is Corcept Therapeutics Incorporated's P/E ratio?
Corcept Therapeutics Incorporated's current P/E ratio is 63.6x. The historical average is 35.3x. This places it at the 90th percentile of its historical range.
What is Corcept Therapeutics Incorporated's EV/EBITDA?
Corcept Therapeutics Incorporated's current EV/EBITDA is 117.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 37.2x.
What is Corcept Therapeutics Incorporated's ROE?
Corcept Therapeutics Incorporated's return on equity (ROE) is 15.0%. The historical average is -53.6%.
Is CORT stock overvalued?
Based on historical data, Corcept Therapeutics Incorporated is trading at a P/E of 63.6x. This is at the 90th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Corcept Therapeutics Incorporated's profit margins?
Corcept Therapeutics Incorporated has 98.3% gross margin and 5.9% operating margin.
How much debt does Corcept Therapeutics Incorporated have?
Corcept Therapeutics Incorporated's Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.